Identification of HER2/ neu-derived peptides capable of inducing both cellular and humoral immune responses in HLA-A24 positive breast cancer patients

Breast Cancer Research and Treatment
Koichi AzumaKyogo Itoh

Abstract

HRE2/neu-specific cellular and humoral immune responses are often detected in breast cancer patients, but identification of more immunogenic CTL epitope peptides is necessary prior to development of a cancer vaccine. There is accumulating evidence of strong immunogenicity of peptides capable of inducing both cellular and humoral immune responses. To identify such peptides, this study intended to determine HER2/neu-derived peptides capable of inducing both cellular and humoral immunity in HLA-A24(+) breast cancer patients. IgGs reactive to the HER2(342-350), HER2(485-493), and HER2(553-561) peptides were detected in the sera of these patients with the frequency of 47, 24, and 24%, respectively. These peptides also induced peptide-specific and tumor-reactive CTL activity in the peripheral blood mononuclear cells of HLA-A24(+) breast cancer patients with the frequency of 50, 63, and 25%, respectively, but such activity was not induced from any HLA-A24(-) patients. Cellular and humoral responses to each of these three peptides were also observed in PBMCs and sera from the other epithelial cancer patients. These results may provide a scientific basis for new clinical trials of HER2/neu-peptide-based immunotherapy for breast cancer a...Continue Reading

References

Jan 17, 1995·Proceedings of the National Academy of Sciences of the United States of America·G E PeoplesT J Eberlein
Nov 18, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L DisisM A Cheever
Oct 12, 2000·Proceedings of the National Academy of Sciences of the United States of America·E JägerA Knuth
Apr 11, 2001·American Journal of Clinical Pathology·F P O'MalleyI Andrulis
Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles L VogelMichael Press
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harold J BursteinEric P Winer

❮ Previous
Next ❯

Citations

Jun 10, 2010·Cancer Immunology, Immunotherapy : CII·Maha Zohra LadjemiIsabelle Navarro-Teulon
Jun 1, 2011·Cancer Immunology, Immunotherapy : CII·Isabel PoschkeRolf Kiessling
Sep 28, 2005·Breast Cancer Research and Treatment·Ben L GuoRichard D Lopez
Jun 2, 2009·Pathologie-biologie·M Z LadjemiI Navarro-Teulon
Feb 14, 2007·The Journal of Urology·Yoshihiro KomoharaKei Matsuoka
Aug 18, 2010·International Journal of Cancer. Journal International Du Cancer·Kousaku MimuraRolf Kiessling
Apr 14, 2016·Proteomics. Clinical Applications·Prachi GuptaYogeshwer Shukla
Jul 18, 2009·Journal of Immunotherapy·Satoko InodaNoriyuki Sato
Aug 24, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Naoki YajimaRyuichi Tanaka

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Mary L DisisKathy Schiffman
Proceedings of the National Academy of Sciences of the United States of America
George E PeoplesTimothy J Eberlein
Breast Cancer Research and Treatment
Kartik MohantyM Bhattacharya-Chatterjee
© 2022 Meta ULC. All rights reserved